Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells.
Histone deacetylases (HDAC) are key enzymes in the epigenetic control of gene expression. Recently, inhibitors of class I and class II HDAC have been successfully employed for the treatment of different inflammatory diseases such as rheumatoid arthritis, colitis, airway inflammation and asthma. So f...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4d86dd49de6a48a4aa897da4d53b42b6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4d86dd49de6a48a4aa897da4d53b42b6 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4d86dd49de6a48a4aa897da4d53b42b62021-11-04T06:08:50ZSirtinol treatment reduces inflammation in human dermal microvascular endothelial cells.1932-620310.1371/journal.pone.0024307https://doaj.org/article/4d86dd49de6a48a4aa897da4d53b42b62011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21931678/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Histone deacetylases (HDAC) are key enzymes in the epigenetic control of gene expression. Recently, inhibitors of class I and class II HDAC have been successfully employed for the treatment of different inflammatory diseases such as rheumatoid arthritis, colitis, airway inflammation and asthma. So far, little is known so far about a similar therapeutic effect of inhibitors specifically directed against sirtuins, the class III HDAC. In this study, we investigated the expression and localization of endogenous sirtuins in primary human dermal microvascular endothelial cells (HDMEC), a cell type playing a key role in the development and maintenance of skin inflammation. We then examined the biological activity of sirtinol, a specific sirtuin inhibitor, in HDMEC response to pro-inflammatory cytokines. We found that, even though sirtinol treatment alone affected only long-term cell proliferation, it diminishes HDMEC inflammatory responses to tumor necrosis factor (TNF)α and interleukin (IL)-1β. In fact, sirtinol significantly reduced membrane expression of adhesion molecules in TNFã- or IL-1β-stimulated cells, as well as the amount of CXCL10 and CCL2 released by HDMEC following TNFα treatment. Notably, sirtinol drastically decreased monocyte adhesion on activated HDMEC. Using selective inhibitors for Sirt1 and Sirt2, we showed a predominant involvement of Sirt1 inhibition in the modulation of adhesion molecule expression and monocyte adhesion on activated HDMEC. Finally, we demonstrated the in vivo expression of Sirt1 in the dermal vessels of normal and psoriatic skin. Altogether, these findings indicated that sirtuins may represent a promising therapeutic target for the treatment of inflammatory skin diseases characterized by a prominent microvessel involvement.Angela OrecchiaClaudia ScarponiFrancesca Di FeliceElisa CesariniSimona AvitabileAntonello MaiMaria Luisa MauroValentina SirriGiovanna ZambrunoCristina AlbanesiGiorgio CamilloniCristina M FaillaPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 9, p e24307 (2011) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Angela Orecchia Claudia Scarponi Francesca Di Felice Elisa Cesarini Simona Avitabile Antonello Mai Maria Luisa Mauro Valentina Sirri Giovanna Zambruno Cristina Albanesi Giorgio Camilloni Cristina M Failla Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. |
| description |
Histone deacetylases (HDAC) are key enzymes in the epigenetic control of gene expression. Recently, inhibitors of class I and class II HDAC have been successfully employed for the treatment of different inflammatory diseases such as rheumatoid arthritis, colitis, airway inflammation and asthma. So far, little is known so far about a similar therapeutic effect of inhibitors specifically directed against sirtuins, the class III HDAC. In this study, we investigated the expression and localization of endogenous sirtuins in primary human dermal microvascular endothelial cells (HDMEC), a cell type playing a key role in the development and maintenance of skin inflammation. We then examined the biological activity of sirtinol, a specific sirtuin inhibitor, in HDMEC response to pro-inflammatory cytokines. We found that, even though sirtinol treatment alone affected only long-term cell proliferation, it diminishes HDMEC inflammatory responses to tumor necrosis factor (TNF)α and interleukin (IL)-1β. In fact, sirtinol significantly reduced membrane expression of adhesion molecules in TNFã- or IL-1β-stimulated cells, as well as the amount of CXCL10 and CCL2 released by HDMEC following TNFα treatment. Notably, sirtinol drastically decreased monocyte adhesion on activated HDMEC. Using selective inhibitors for Sirt1 and Sirt2, we showed a predominant involvement of Sirt1 inhibition in the modulation of adhesion molecule expression and monocyte adhesion on activated HDMEC. Finally, we demonstrated the in vivo expression of Sirt1 in the dermal vessels of normal and psoriatic skin. Altogether, these findings indicated that sirtuins may represent a promising therapeutic target for the treatment of inflammatory skin diseases characterized by a prominent microvessel involvement. |
| format |
article |
| author |
Angela Orecchia Claudia Scarponi Francesca Di Felice Elisa Cesarini Simona Avitabile Antonello Mai Maria Luisa Mauro Valentina Sirri Giovanna Zambruno Cristina Albanesi Giorgio Camilloni Cristina M Failla |
| author_facet |
Angela Orecchia Claudia Scarponi Francesca Di Felice Elisa Cesarini Simona Avitabile Antonello Mai Maria Luisa Mauro Valentina Sirri Giovanna Zambruno Cristina Albanesi Giorgio Camilloni Cristina M Failla |
| author_sort |
Angela Orecchia |
| title |
Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. |
| title_short |
Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. |
| title_full |
Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. |
| title_fullStr |
Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. |
| title_full_unstemmed |
Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. |
| title_sort |
sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2011 |
| url |
https://doaj.org/article/4d86dd49de6a48a4aa897da4d53b42b6 |
| work_keys_str_mv |
AT angelaorecchia sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells AT claudiascarponi sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells AT francescadifelice sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells AT elisacesarini sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells AT simonaavitabile sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells AT antonellomai sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells AT marialuisamauro sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells AT valentinasirri sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells AT giovannazambruno sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells AT cristinaalbanesi sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells AT giorgiocamilloni sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells AT cristinamfailla sirtinoltreatmentreducesinflammationinhumandermalmicrovascularendothelialcells |
| _version_ |
1718445148650602496 |